Deverra Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Crowdfunding

  • Latest Deal Amount
  • $979K

  • Investors
  • 4

Deverra Therapeutics General Information

Description

Developer of a biotechnology platform designed to generate off-the-shelf allogeneic cellular immunotherapies. The company's platform helps in the production of progenitor blood and immune cells for clinical application to treat cancer and infectious diseases, enabling patients suffering from hematologic malignancies and other critical diseases to be cured.

Contact Information

Formerly Known As
IMMUNI-T
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1600 Fairview Avenue East
  • Suite 300
  • Seattle, WA 98102
  • United States
+1 (206)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 1600 Fairview Avenue East
  • Suite 300
  • Seattle, WA 98102
  • United States
+1 (206)

Deverra Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Deverra Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Equity Crowdfunding 04-Sep-2024 $979K Completed Clinical Trials - Phase 1
4. Early Stage VC 18-Sep-2023 Completed Clinical Trials - Phase 1
3. Grant 01-Sep-2023 Completed Clinical Trials - Phase 1
2. Early Stage VC 27-Aug-2020 $75K $75K Completed Startup
1. Early Stage VC 01-Jan-2019 Completed Startup
To view Deverra Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Deverra Therapeutics Patents

Deverra Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023338109-A1 Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells Pending 07-Sep-2022
EP-4583891-A1 Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells Pending 07-Sep-2022
EP-4583891-A4 Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells Pending 07-Sep-2022
US-20260355236-A1 Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells Pending 07-Sep-2022
WO-2024054769-A1 Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells Inactive 07-Sep-2022 A61K40/17
To view Deverra Therapeutics’s complete patent history, request access »

Deverra Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Deverra Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
D3VC Venture Capital Minority
Andy Hill Care Fund Government
5AM Ventures Venture Capital Minority
Sorrento Therapeutics Corporation Minority
To view Deverra Therapeutics’s complete investors history, request access »

Deverra Therapeutics FAQs

  • When was Deverra Therapeutics founded?

    Deverra Therapeutics was founded in 2019.

  • Where is Deverra Therapeutics headquartered?

    Deverra Therapeutics is headquartered in Seattle, WA.

  • What is the size of Deverra Therapeutics?

    Deverra Therapeutics has 14 total employees.

  • What industry is Deverra Therapeutics in?

    Deverra Therapeutics’s primary industry is Biotechnology.

  • Is Deverra Therapeutics a private or public company?

    Deverra Therapeutics is a Private company.

  • What is the current valuation of Deverra Therapeutics?

    The current valuation of Deverra Therapeutics is .

  • What is Deverra Therapeutics’s current revenue?

    The current revenue for Deverra Therapeutics is .

  • How much funding has Deverra Therapeutics raised over time?

    Deverra Therapeutics has raised $3.44M.

  • Who are Deverra Therapeutics’s investors?

    D3VC, Andy Hill Care Fund, 5AM Ventures, and Sorrento Therapeutics have invested in Deverra Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process